Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRHDE | Q9UKU6 | 1/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.45 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.45 |
| ▸ | TRHR | P34981 | 1/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
| ▸ | CPB1 | P15086 | 1/20 | 0.38 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL888799 | 1.00 | TRHDE (0.47) | TRHDECDK5CDK5R1TRHRCPB2 | |
| SCHEMBL755381 | 0.90 | TRHDE (0.54) | TRHDECDK5CDK5R1TRHRCPB2 | |
| SCHEMBL14864806 | 0.89 | TRHDE (0.48) | TRHDECDK5CDK5R1TRHRCPB2 | |
| SCHEMBL868827 | 0.89 | TRHDE (0.48) | TRHDECDK5CDK5R1TRHRCPB2 | |
| SCHEMBL10228107 | 0.87 | TRHDE (0.47) | TRHDECDK5CDK5R1TRHRCPB2 | |
| SCHEMBL16229730 | 0.86 | TRHDE (0.48) | TRHDECDK5CDK5R1TRHRCPB2 | |
| SCHEMBL846556 | 0.86 | TRHDE (0.48) | TRHDECDK5CDK5R1TRHRCPB2 | |
| SCHEMBL8906686 | 0.86 | TRHDE (0.48) | TRHDECDK5CDK5R1TRHRCPB2 | |
| SCHEMBL19508750 | 0.80 | KLK5 (0.51) | TRHDECYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL13984143 | 0.80 | TRHDE (0.50) | TRHDECDK5CDK5R1TRHRCPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017499-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-9676802-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARM INC (US) | 2017-04-27 | — | — | US | disclosed |
| US-8822700-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140193363-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8703938-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8673954-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2012-03-29 | — | — | US | disclosed |
| US-8143414-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110098327-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-28 | — | — | US | disclosed |
| US-20110064695-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110064696-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110008288-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | TRHDE 4725/4885CDK5 142/4885CDK5R1 316/4885 |
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | TRHDE 4725/4885CDK5 142/4885CDK5R1 316/4885 |
| US-10017499-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | TRHDE 4671/4885CDK5 227/4885CDK5R1 595/4885 |
| US-20110008288-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | TRHDE 4605/4885CDK5 325/4885CDK5R1 689/4885 |
| US-20110064695-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | TRHDE 4645/4885CDK5 426/4885CDK5R1 788/4885 |
| US-20110064696-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | TRHDE 4645/4885CDK5 426/4885CDK5R1 788/4885 |
| US-20140193363-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | TRHDE 4725/4885CDK5 142/4885CDK5R1 316/4885 |
| US-20110098327-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | TRHDE 4834/4885CDK5 1414/4885CDK5R1 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.